Optineurin dysfunction induces neurodegeneration in normal tension glaucoma by a novel molecular mechanism
Optineurin功能障碍通过一种新的分子机制诱导正常眼压青光眼的神经变性
基本信息
- 批准号:10372873
- 负责人:
- 金额:$ 54.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:Amyotrophic Lateral SclerosisAnimal ModelAutophagocytosisAxonAxonal TransportBiochemicalBiological AssayBiotinBlindnessCell DeathCytokine SignalingDataEnvironmentFailureFunctional disorderGene MutationGenesGlaucomaGoalsHistologicHumanHybridsImpairmentInheritedInterventionLinkMediatingMitochondriaModelingMolecularMonitorMorphologyMusMutationNerve DegenerationNeuronsOcular HypertensionOptic NervePathogenesisPathogenicityPathway interactionsPatientsPhenotypePhysiologic Intraocular PressurePlayPopulationPositioning AttributeProteinsRetinaRetinal Ganglion CellsRoleScientistStructureTestingTherapeuticTimeTransgenic MiceVacuumVesicleYeastsaxonal degenerationaxonopathybasecDNA Librarycausal variantcellular imagingexperimental studygene functionin vivomouse modelmutantneural repairneuronal cell bodyneuronal survivalneuroprotectionnew therapeutic targetnoveloptic nerve disorderoverexpressionreceptorretinal axonsyntaphilintooltrafficking
项目摘要
PROJECT SUMMARY
Normal tension glaucoma (NTG) is characterized by optic neuropathy with progressive retinal ganglion cell
(RGC) death and optic nerve (ON) degeneration but in the absence of intraocular pressure (IOP) elevation. All
current glaucoma treatments are to lower IOP and are less effective in NTG patients. The primary reasons for
the therapeutic vacuum are the limited understanding of the molecular mechanisms of IOP-independent
glaucomatous degeneration and the lack of a practical and effective NTG animal model. Causal mutations in the
optineurin gene (OPTN) have been found in familial and sporadic NTG. Interestingly, OPTN mutations also
cause inherited forms of another CNS axonopathy, amyotrophic lateral sclerosis (ALS), indicating a common
degenerative machinery that can be activated by dysfunctional OPTN in vulnerable CNS neuronal populations.
However, although OPTN has been extensively studied and its various roles in autophagy, cytokine signaling,
and vesicle trafficking have been found, the pathophysiology role of OPTN in CNS neurodegeneration are far
from clear. We have recently established a highly efficient NTG mouse model by truncating OPTN gene in RGCs
specifically, which presents significant RGCs and ON degeneration within weeks. Using this novel NTG model,
we propose to investigate how OPTN mutation causes neurodegeneration in vivo through validating and
characterizing OPTN-interacting proteins in RGCs and ON. Through these studies, we will generate essential
information to uncover novel molecular mechanisms of glaucomatous neurodegeneration related with OPTN that
may be also shared by ALS and other CNS axonopathies, identify novel modifiers of RGC/ON
neurodegeneration, and provide valuable tools and animal models to develop neuroprotection therapies.
项目摘要
正常眼压性青光眼(Normal tension glaucoma,NTG)是一种以视网膜神经节细胞进展为特征的视神经病变
(RGC)死亡和视神经(ON)变性,但没有眼内压(IOP)升高。所有
目前的青光眼治疗是降低IOP,并且在NTG患者中效果较差。的主要原因
治疗真空是对IOP非依赖性的分子机制的有限理解
目前还缺乏实用有效的NTG动物模型。基因突变
在家族性和散发性NTG中发现了视神经磷酸酶基因(optineurin,OPTN)。有趣的是,OPTN突变也
引起另一种CNS轴突病的遗传形式,肌萎缩侧索硬化症(ALS),表明一种常见的
在脆弱的CNS神经元群体中,可以通过功能失调的OPTN激活退行性机制。
然而,尽管OPTN已经被广泛研究,并且其在自噬、细胞因子信号传导、
和囊泡运输的发现,OPTN在中枢神经系统退行性变中的病理生理作用还远未阐明
从Clear我们最近建立了一个高效的NTG小鼠模型,通过截断RGC中的OPTN基因
具体地,其在数周内呈现显著的RGC和ON变性。使用这种新的NTG模型,
我们建议通过验证和研究OPTN突变如何导致体内神经退行性变,
表征RGC和ON中的OPTN相互作用蛋白。通过这些研究,我们将产生必要的
揭示与OPTN相关的青光眼神经退行性变的新分子机制的信息,
也可能是ALS和其他CNS轴突病共有的,鉴定RGC/ON的新修饰剂
神经退行性变,并提供有价值的工具和动物模型,以开发神经保护疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yang Hu其他文献
Yang Hu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yang Hu', 18)}}的其他基金
In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser Ophthalmology
双光子扫描激光眼科评价青光眼 RGC 的体内功能和代谢
- 批准号:
10660761 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Mechanisms of peroxisome proliferator-activated receptor-alpha regulation in peridontitis
过氧化物酶体增殖物激活受体-α在牙周炎中的调节机制
- 批准号:
10915090 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Optineurin dysfunction induces neurodegeneration in normal tension glaucoma by a novel molecular mechanism
Optineurin功能障碍通过一种新的分子机制诱导正常眼压青光眼的神经变性
- 批准号:
10557146 - 财政年份:2022
- 资助金额:
$ 54.57万 - 项目类别:
Neuroprotection by Modulating ER Stress in Glaucoma
通过调节 ER 应激对青光眼进行神经保护
- 批准号:
10390110 - 财政年份:2021
- 资助金额:
$ 54.57万 - 项目类别:
Pathogenic role of peroxisome proliferator-activated receptor alpha in periodontitis
过氧化物酶体增殖物激活受体α在牙周炎中的致病作用
- 批准号:
10363668 - 财政年份:2021
- 资助金额:
$ 54.57万 - 项目类别:
Developing Novel Neuroprotective Strategies for EAE/Optic Neuritis
开发针对 EAE/视神经炎的新型神经保护策略
- 批准号:
10200056 - 财政年份:2018
- 资助金额:
$ 54.57万 - 项目类别:
Neuroprotection by Modulating ER Stress in Glaucoma
通过调节 ER 应激对青光眼进行神经保护
- 批准号:
9430478 - 财政年份:2017
- 资助金额:
$ 54.57万 - 项目类别:
Elucidating Neuron-Intrinsic Molecular Mechanisms of Optic Nerve Regeneration
阐明视神经再生的神经元固有分子机制
- 批准号:
9438581 - 财政年份:2016
- 资助金额:
$ 54.57万 - 项目类别:
Elucidating Neuron-Intrinsic Molecular Mechanisms of Optic Nerve Regeneration
阐明视神经再生的神经元固有分子机制
- 批准号:
9316634 - 财政年份:2016
- 资助金额:
$ 54.57万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 54.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists